|Bid||82.17 x 800|
|Ask||84.99 x 800|
|Day's Range||83.61 - 84.71|
|52 Week Range||57.00 - 96.33|
|Beta (3Y Monthly)||1.13|
|PE Ratio (TTM)||164.86|
|Earnings Date||Feb 13, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||88.73|
Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
Incyte slightly beat our expectations for 2018 thanks to stronger other revenue, but its 2019 guidance was in line with our assumptions. The company's narrow economic moat is supported by Jakafi's dominance, and its positive moat trend is supported by expanding Jakafi approvals and a growing late-stage pipeline. Incyte has $1.4 billion in cash, which we expect it could use to add to its late-stage pipeline.
Incyte earnings lagged expectations in the fourth quarter, but the company turned around from a year-earlier loss as sales beat estimates — prodding Incyte stock to rise Thursday.
Baker Bros., which was among the top 20 holders of the biotech stock at the end of September, sold its final 567,497 shares by the end of 2018, according to a regulatory filing this week. Baker Bros. didn’t immediately respond to a request for comment. To be sure, the New York-based hedge fund held just under half a million shares back in 2017 when Sage approached $100 per share after its lead asset saw success in another clinical trial.
Incyte (INCY) delivered earnings and revenue surprises of -6.98% and 0.47%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Wilmington, Delaware-based company said it had profit of 32 cents per share. Earnings, adjusted for stock option expense and amortization costs, were 40 cents per share. The results missed Wall Street ...
WILMINGTON, Del.-- -- Total product-related revenues of $468 million in 4Q 2018 and $1.7 billion for the full year 2018 Jakafi ® revenues of $380 million in 4Q 2018 and $1.4 billion for the full year 2018 Multiple late-stage product candidates provide additional opportunities to further accelerate revenue growth Conference Call and Webcast Scheduled Today at 8:00 a.m. EST Incyte Corporation today ...
Investing.com - Incyte (NASDAQ:INCY) reported fourth quarter earnings that beat analysts' expectations on Thursday and revenue that topped forecasts.
is expected to report earnings of 17 cents a share on sales of $486.2 million before the market opens Feb. 14, based on a FactSet survey of 10 analysts. The stock has risen 33.4% since the company last reported earnings on Oct. 30. Incyte is currently trading at a price-to-forward-earnings ratio of 56.1 based on the 12-month estimates of 19 analysts surveyed by FactSet.
Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.
Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.
The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.
Incyte Corp NASDAQ/NGS:INCYView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for INCY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding INCY totaled $14.27 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Incyte stock dipped Thursday after the Food and Drug Administration unexpectedly delayed its graft vs. host disease treatment by three months. The FDA is now set to review the drug in May.
A ruling on the Wilmington biotech company's supplemental application for Jakafi will occur in May.
Incyte (INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi®) for the treatment of patients with acute graft-versus-host disease (GVHD) who have had an inadequate response to corticosteroids. The FDA extended the action date to allow time to review additional data submitted by Incyte in response to the FDA’s information requests. The submission of the additional information has been determined by the FDA to constitute a Major Amendment to the sNDA, resulting in an extension of the PDUFA goal date by three months.